Coverage: The Meridian legal market record (editorial).
The licence's country list is built around low- and middle-income countries and Sub-Saharan African markets are within it; the MPP licence page states the instrument and the 129-country scope, and the MPP sublicences that follow are signed with African manufacturers (recorded separately).
| Record ID | TX-AFR-2026-0020 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, Non-exclusive licence, Technology transfer, In-licensing |
| IP rights | patent, know-how, regulatory data |
| Status | Signed |
| Qualifying date | 2026-05 (month precision) |
| Sector | Life sciences · Pharmaceuticals – antivirals |
| African markets | Multi-jurisdictional |
| Licensed territory | 129 low- and middle-income countries, subject to local regulatory authorisation. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, independently corroborated · 2 source(s) |
| Last verified | 2026-10-25 |
Parties
- Medicines Patent Pool Foundation (Switzerland): licensee, sublicensor
- F. Hoffmann-La Roche (Switzerland): licensor
Key terms
- Interest: non-exclusive licence (with right to sublicense); Exclusivity: non-exclusive; Territorial scope: 129 low- and middle-income countries
Sources
- Baloxavir marboxil licence (Roche / MPP), Medicines Patent Pool, 2026-05-15
- Uganda's Qcil Wins Licence to Develop Generic Influenza Treatment, ChimpReports, 2026-09-25
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


